• Home
  • Search Results
  • Obstetric and neonatal outcomes after preterm premature rupture of membranes among women carrying group B streptococcus.

Obstetric and neonatal outcomes after preterm premature rupture of membranes among women carrying group B streptococcus.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2015-01-15)
Yael Ganor-Paz, David Kailer, Gil Shechter-Maor, Rivka Regev, Moshe D Fejgin, Tal Biron-Shental
ABSTRACT

To evaluate whether carriers of group B streptococcus (GBS) have adverse obstetric and neonatal outcomes when preterm premature rupture of membranes (PPROM) occurs. In a retrospective study, data were reviewed for women with a singleton pregnancy and PPROM before 34 weeks who attended the Meir Medical Center, Kfar Saba, Israel, between 2005 and 2012. All women received roxithromycin for 1 week, and ampicillin until GBS culture results were available. Ampicillin was continued to 1 week if the GBS culture was positive. The primary study outcome measure was the latency period (time from rupture of membranes to active/induced labor). Among 116 eligible patients, 21 (18.1%) were GBS carriers and 95 (81.9%) noncarriers. The latency period was 11.2 ± 18.1 days for GBS carriers versus 7.5 ± 9.6 days for noncarriers (P=0.93). However, there was a correlation between the length of ampicillin treatment and the latency period (Spearman correlation coefficient 0.7; P<0.001). There were no differences in early neonatal outcomes. GBS carriers with PPROM did not have adverse outcomes. Longer treatment with ampicillin among GBS carriers prolonged the latency period.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ampicillin, anhydrous, 96.0-102.0% (anhydrous basis)
Supelco
Ampicillin, analytical standard
Sigma-Aldrich
Ampicillin, meets USP testing specifications
Supelco
Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Roxithromycin, 95.0-102.0% (HPLC)
Sigma-Aldrich
Betamethasone, ≥98%
USP
Ampicillin, United States Pharmacopeia (USP) Reference Standard
Ampicillin, anhydrous, European Pharmacopoeia (EP) Reference Standard
USP
Betamethasone, United States Pharmacopeia (USP) Reference Standard
Betamethasone, European Pharmacopoeia (EP) Reference Standard
Supelco
Betamethasone, VETRANAL®, analytical standard
Roxithromycin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
Betamethasone, meets USP testing specifications